The news that Biodexa Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement is positive as it ensures the company's continued listing on the exchange. This removes the risk of delisting, which could have negatively impacted investor confidence and stock price. The compliance indicates stability and may lead to a positive short-term impact on the stock price.